A Phase III Randomized Double-Blind Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric ad Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)

Brief description of study

If you have been diagnosed with locally advanced resectable gastric or GEJ adenocarcinoma, you may qualify to participate in a study evaluating the overall survival benefit in patients treated with Pembrolizumab (KEYTRUDA®) and chemotherapy compared to those receiving placebo and chemotherapy. This is a randomized phase ill study testing the potential benefit of Pembrolizumab (KEYTRUDA®) in the treatment of locally advanced gastroesophageal cancer. In addition, we will also evaluate how your quality of life is affected by your disease and the assigned treatment plan.


Clinical Study Identifier: s17-00495
ClinicalTrials.gov Identifier: NCT03221426
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.